ES2087173T3 - Uso de derivados de piridoindol en el tratamiento de enfermedades isquemicas. - Google Patents

Uso de derivados de piridoindol en el tratamiento de enfermedades isquemicas.

Info

Publication number
ES2087173T3
ES2087173T3 ES91104036T ES91104036T ES2087173T3 ES 2087173 T3 ES2087173 T3 ES 2087173T3 ES 91104036 T ES91104036 T ES 91104036T ES 91104036 T ES91104036 T ES 91104036T ES 2087173 T3 ES2087173 T3 ES 2087173T3
Authority
ES
Spain
Prior art keywords
hydrogen
ischemic diseases
piridoindol
derivatives
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91104036T
Other languages
English (en)
Inventor
Masayuki Kato
Kiyotaka Ito
Hisashi Takasugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2087173T3 publication Critical patent/ES2087173T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

UN USO DE UN COMPUESTO DE LA FORMULA: DONDE R ELEVADO 1 ES HIDROGENO, ALQUILO MAS BAJO, ALQUENILO MAS BAJO O N,N-DI (MAS BAJO) ALQUILAMINOMETILO, R (AL CUADRADO) ES HIDROGENO, ALQUILO MAS BAJO O HALOGENO, R ELEVADO 3 ES IMIDAZOLILO O PIRIDILO, CADA UNO DE LOS CUALES PUEDE TENER SUSTITUTOS ADECUADOS, Y R ELEVADO 4 ES HIDROGENO, ALQUILO MAS BAJO, ALQUENILO MAS BAJO, O HIDROXIALQUILO MAS BAJO Y R ELEVADO 5 ES HIDROGENO, HIDROXI O ACICLOXI, O R ELEVADO 4 Y R ELEVADO 5 ESTAN UNIDOS PARA FORMAR UN ENLACE ADICIONAL, O UNA SAL SUYA ACEPTABLE FARMACEUTICAMENTE, PARA TRATAR ENFERMEDADES ISQUEMICAS.
ES91104036T 1990-03-19 1991-03-15 Uso de derivados de piridoindol en el tratamiento de enfermedades isquemicas. Expired - Lifetime ES2087173T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/495,119 US5173493A (en) 1988-09-27 1990-03-19 Pyridoindole derivatives and processes for preparation thereof

Publications (1)

Publication Number Publication Date
ES2087173T3 true ES2087173T3 (es) 1996-07-16

Family

ID=23967334

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91104036T Expired - Lifetime ES2087173T3 (es) 1990-03-19 1991-03-15 Uso de derivados de piridoindol en el tratamiento de enfermedades isquemicas.

Country Status (11)

Country Link
US (1) US5173493A (es)
EP (1) EP0451538B1 (es)
JP (1) JP3074799B2 (es)
KR (1) KR100192863B1 (es)
AT (1) ATE138265T1 (es)
CA (1) CA2038527A1 (es)
DE (1) DE69119642T2 (es)
DK (1) DK0451538T3 (es)
ES (1) ES2087173T3 (es)
GR (1) GR3020020T3 (es)
TW (1) TW224973B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
CA2157671A1 (en) * 1993-03-08 1994-09-15 Kiyotaka Katsuta Medicament for treating or preventing cerebrovascular diseases
DE69525354T2 (de) * 1994-09-19 2002-08-14 Fujisawa Pharmaceutical Co Eine neuartige medizinische verwendung eines 5ht 3-antagonisten
AU7000696A (en) * 1995-09-22 1997-04-09 Fujisawa Pharmaceutical Co., Ltd. Novel processes for producing pyridoindole derivatives
EP2033632A1 (en) * 2007-09-10 2009-03-11 Novasearch AG 5-HT3 receptor antagonists for the teatment of myocardial infarction, stroke, thrombosis and atherosclerosis

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1182150B (it) * 1984-01-25 1987-09-30 Glaxo Group Ltd Composti eterociclici tetraidrocarbozolonici, procedimenti per preparli e composizioni farmaceutiche che li contengono
EP0252643A1 (en) * 1986-07-01 1988-01-13 BEECHAM - WUELFING GmbH & Co. KG Pyrido[1,2-a]indole derivatives, process for their preparation and pharmaceutical compounds containing them
GB8802127D0 (en) * 1988-02-01 1988-03-02 Glaxo Group Ltd Chemical compounds
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof

Also Published As

Publication number Publication date
EP0451538B1 (en) 1996-05-22
ATE138265T1 (de) 1996-06-15
JP3074799B2 (ja) 2000-08-07
DK0451538T3 (da) 1996-06-17
EP0451538A3 (en) 1992-04-15
CA2038527A1 (en) 1991-09-20
US5173493A (en) 1992-12-22
DE69119642D1 (de) 1996-06-27
TW224973B (es) 1994-06-11
EP0451538A2 (en) 1991-10-16
KR910016331A (ko) 1991-11-05
DE69119642T2 (de) 1996-11-14
KR100192863B1 (ko) 1999-06-15
JPH04270280A (ja) 1992-09-25
GR3020020T3 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
NO913750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
DE69716226T2 (de) Difluoroprostaglandin-Derivate und ihre Anwendung
ES2055235T3 (es) Composicion anti-inflamatoria y/o antialergica que comprende derivados de glutation.
ES2087173T3 (es) Uso de derivados de piridoindol en el tratamiento de enfermedades isquemicas.
DK0420121T3 (da) Antitumormiddel
WO1994020102A3 (en) Medicament for treating or preventing cerebrovascular diseases
NO172541C (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyridoindol-derivater
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
FI944687A0 (fi) Koostumus likinäköisyyden ennaltaehkäisemiseksi ja hoitamiseksi
NO952194L (no) Spirofuranonderivater og deres anvendelse ved behandling av neurodegenerative sykdommer
EP0272849A3 (en) Use of 2-oxo-imidazolidine derivatives in the treatment of kidney diseases
KR920002139A (ko) 뇌혈관 수축 치료제
GR1000522B (el) Μεθοδος παρασκευης νεων αναλογων νουκλεοζιτων.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 0451538

Country of ref document: ES